Skip to main content
Marc Berger, M.D.

Marc Berger, M.D.
Vice President, Real World Data and Analytics, Pfizer

Marc L. Berger, M.D. is Vice President, Real World Data and Analytics at Pfizer. Prior to joining Pfizer in September 2012, he was Executive Vice President and Senior Scientist, in the life sciences group of OptumInsight (formerly known as Ingenix). A native of New York, he has held senior positions in the pharmaceutical industry including Vice President, Outcomes Research and Management at Merck & Co., Inc. from 2002 – 2007, and Vice President, Global Health Outcomes, at Eli Lilly and Company from 2007 – 2011. He obtained an M.D. degree from Johns Hopkins University School of Medicine and has held adjunct appointments as Senior Fellow at the Leonard Davis Institute at the Wharton School of the University of Pennsylvania and Professor in the Department of Health Policy and Administration at the University of North Carolina at Chapel Hill School of Public Health. He has served on the Medicare Evidence Development & Coverage Advisory Committee (MedCAC) for the Center for Medicare & Medicaid Services (CMS), the board of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the steering committee for the Agency for Health Care Research and Quality (AHRQ) Centers for Research and Education on Therapeutics (CERTs), the board of the Health Industry Forum of the Heller School for Social Policy and Management at Brandeis University and the Editorial Advisory Board of Value in Health. He recently served as co-chair of the ISPOR Taskforce on Prospective Observational Studies for Comparative Effectiveness Research. Currently, he is a member of the editorial advisory board of the Journal of Comparative Effectiveness Research, the advisory council for North America (ACNA) of the Drug Information Association (DIA) and the Green Park Collaborative on HTA/Payer Methods Guidance coordinated by the Center for Medical Technology Policy (CMTP). He also currently serves as chair of the AMCP/NPC/ISPOR Comparative Effectiveness Collaborative Initiative Taskforce for the Interpreting Prospective Observational Studies for Health Care Decisions. Marc has written or co-written more than 100 peer-reviewed articles, book chapters, and other publications on a range of topics including health services research, outcomes research, health economics, and health policy. He co-edited “Health Care, Cost, Quality, and Outcomes – ISPOR Book of Terms” which was published in 2003 and was subsequently translated into nine languages.

Sessions

Table A
- Big Data and Advanced Analytics for Drug Development - Policy environment for access to Big Data - Need for collaborative partnerships to advance Big Data Read more.
Pioneers and leaders in comparative effectiveness and pharma health economics and outcomes research and real world data will debate the various challenges posed by the evolving need to extract evidence from clinical trial and real world data. Read more.

For exhibition and sponsorship opportunities at Strata Rx conference, contact Sharon Pierce at (203) 304-9476 or spierce@oreilly.com

For information on trade opportunities with O'Reilly conferences email mediapartners
@oreilly.com

View a complete list of Strata Rx 2013 contacts